Company intelligence / Profile preview
Halodine
Spring House, Pennsylvania, United Stateshalodine.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Halodine has developed proprietary nasal and oral antiseptics that have demonstrated rapid inactivation of SARS-CoV-2, the virus responsible for COVID‑19, in less than 15 seconds. The products are marketed as providing up to 4 hours of protection, with clinical validation against SARS-CoV‑2. Ongoing collaborations aim to expand efficacy data against other clinically important pathogens, including drug-resistant hospital-acquired infections[1][2][3].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculeAntiseptic (topical)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Emery Pharma[3][6]
Beyond the preview
Go deeper on Halodine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Halodine.